CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).
The TGA said it had not received any reports of inflammatory brain disorders occurring in Australian patients who have been prescribed Zinbryta, but Biogen is coordinating a worldwide withdrawal, with supply in Australia continuing until 31 May 2018 allowing patients time to gradually transition off the medicine.
The TGA further warned that adverse drug reactions to Zinbryta could potentially occur up to six months after discontinuation.
See more at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 18
